UGCG and autosomal dominant polycystic kidney disease: Recently, the trial in ADPKD with Venglustat (Glucosylceramide synthase inhibitor; Natoli et al., 2010) was discontinued as it did not reduce TKV growth rate (https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-01-05-00-00-2239122).